REG - Sareum Holdings PLC - Update on TYK2/JAK1 and SRA737 Programmes

Sareum HoldingsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb3260Ga&default-theme=true

RNS Number : 3260G  Sareum Holdings PLC  28 April 2025

 

Sareum Holdings PLC

 

("Sareum" or the "Company")

 

Update on TYK2/JAK1 and SRA737 Programmes

Cambridge, UK, 28 April 2025 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, today provides an update on its
TYK2/JAK1 and SRA737 programmes.

"Brain-penetrant" TYK2 inhibitors

Sareum has recently conducted targeted preclinical studies to evaluate the
potential of its TYK2/JAK1 compounds in central nervous system ("CNS")
indications. This work reflects growing scientific and commercial interest in
the role of TYK2 inhibition in neuroinflammatory diseases such as Multiple
Sclerosis, Parkinson's Disease, and Alzheimer's Disease - all areas with
significant unmet medical need.

The study involved six compounds from Sareum's proprietary Sareum Kinase
Inhibitor Library ("SKIL") platform, tested in preclinical models to assess
their ability to cross the blood-brain barrier ("BBB") - a key requirement for
CNS drug development. Three compounds demonstrated meaningful BBB penetration,
with one showing strong levels of free drug in the brain.

While further optimisation is still required, the results support the
potential for Sareum's TYK2/JAK1 chemistry to be applied to CNS indications.

The Company is assessing the potential next steps for these compounds,
including whether to progress one or more into preclinical development.

SRA737

SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that
targets cancer cell replication and DNA damage repair mechanisms. Sareum has
now received the full clinical dataset for SRA737, following the termination
of its licensing agreement with a US-based partner in December 2024. This
includes the Trial Master File and all associated documentation - these data
amount to approximately 235Gb. With full operational control attained, Sareum
is now positioned to conduct a comprehensive review of the programme's
potential.

Strategic options under consideration include re-licensing the asset or
advancing it in-house with or without a partner. The former licensee has
expressed continued confidence in SRA737's clinical profile, which Sareum
believes will support potential future partnering discussions. A decision on
the optimal path forward will be made in the context of broader pipeline
priorities including the opportunity to enhance shareholder value through
partnering or re-licensing.

Ongoing development of SDC-1801 and SDC-1802

Sareum continues to advance its lead autoimmune and oncology programmes:

·    SDC-1801, a selective TYK2/JAK1 inhibitor for autoimmune diseases,
has completed Phase I clinical development, demonstrating a favourable safety
and pharmacokinetic profile. Comprehensive data from the Phase I study has now
been published
(https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385663&showOriginal=true&isReview=true)
on the Australian New Zealand Clinical Trials Registry (ANZCTR).  A 16-week
toxicology study to support longer-term dosing is expected to commence in May
2025, with completion anticipated in Q4.

·    SDC-1802, a TYK2/JAK1 inhibitor for immuno-oncology applications,
remains in preclinical development. Sareum is continuing translational work to
define optimal cancer indications and patient populations prior to advancing
SDC-1802 toward first-in-human studies.

These programmes represent Sareum's most advanced assets and form the
foundation of its near-term clinical strategy.

Dr Stephen Parker, Executive Chairman of Sareum, commented:

"Our recent preclinical findings show that our TYK2/JAK1 inhibitors have
significant potential to be developed for CNS diseases - a strategically
important area with high unmet need. Regaining full control of SRA737 also
provides us with the flexibility to determine the best route forward based on
robust data. Alongside our advancing clinical programmes, we are building
optionality and long-term value across the pipeline."

 

- Ends -

 

For further information, please contact:

 

 Sareum Holdings plc

 Stephen Parker, Executive Chairman         01223 497700

                                            ir@sareum.co.uk (mailto:ir@sareum.co.uk)

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Oberon Capital (Joint Broker)

 Mike Seabrook / Nick Lovering              020 3179 5300

 Hybridan LLP (Joint Broker)

 Claire Noyce                               020 3764 2341

 ICR Healthcare (Financial PR)

 Jessica Hodgson / Davide Salvi             0203 709 5700

 

 

About Sareum

 

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

 

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, including
psoriasis, and has completed Phase 1 clinical development.

 

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

 

The Company has recently acquired the licence for SRA737, a clinical-stage
Checkpoint Kinase 1 inhibitor that targets cancer cell replication and DNA
damage repair mechanisms.

 

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCIRMPTMTATMMA